PIK3CD Antibody

1. findings suggest that the increased circulating transitional B cells characteristic of PIK3CD5 are related to abnormal B-cell maturation in the bone marrow PMID:27697496
2. Data show that mRNA translation stress induces E2F transcription factor 1 (E2F1) via PI3-kinase p110 subunit delta (PI3Kdelta). PMID:29235459
3. our work describing two new PIK3CD gain-of-function mutations, E81K and G124D, demonstrated that mutations in the ABD and its linker region lead to APDS1. PMID:28428270
4. CXCR4 can induce PI3Kdelta inhibitor resistance in ABC DLBCL. PMID:29472546
5. results suggest that the different isoforms of the PI3K p110 subunit could be therapeutic targets for primary and metastatic colon cancer and that regulation of the NRD1/ADAM signaling pathway controls lipogenesis-mediated EMT in IGF-1-stimulated colon cancer cells. PMID:28819788
6. Results provide molecular insights into the conformational mechanisms by which PI3Kdelta is activated in primary immunodeficiencies and reveal how mutations in PIK3R1 (p85alpha) can specifically phenocopy gain-of-function mutations in PIK3CD (p110delta). PMID:28167755
7. Idelalisib is a selective inhibitor of phosphatidylinositol-3-kinase delta (PI3Kdelta) that inhibits Hodgkin lymphoma growth and survival . Based on the above preclinical data, the current study evaluated the efficacy and safety of idelalisib in relapsed and refractory Hodgkin lymphoma . PMID:28327905
8. PI3Kdelta and PI3Kgamma inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK PMID:27174919
9. Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. PMID:26961147
10. miR-26b inhibited the PI3K/AKT pathway by directly targeting PIK3CD, the gene encoding PI3Kdelta, in human T-ALL cell lines PMID:28280276
11. Targeting PI3Kdelta or JAK may prove effective in reducing T-cell activation and the resulting cytokine production in asthma. PMID:27716212
12. Our work defines SETD2 as a tumor suppressor gene in Hepatosplenic T-cell lymphoma (HSTL)and implicates genes including INO80 and PIK3CD in the disease PMID:28122867
13. The findings, specifically frequent mutations of STAT5B, PIK3CD, and the histone methyltransferase SETD2, may help guide translational efforts to target hepatosplenic T-cell lymphoma PMID:28373165
14. PI3K, independently of protein kinase B, has a role in parasite-induced netosis. One of the main isoforms involved is PI3Kdelta, which works in a reactive-oxygen-species-independent way. PMID:27154356
15. The B-cell compartment in PI3K-delta syndrome patients is affected by the mutations in PIK3CD and PIK3R1. There is reduced differentiation beyond the transitional stage, increased AKT phosphorylation and increased apoptosis. PMID:28104464
16. PI3Kdelta or Bruton's tyrosine kinase inhibitors increase genomic instability in normal and neoplastic B cells by an AID-dependent mechanism; this effect should be carefully considered, as such inhibitors can be administered to patients for years PMID:28199309
17. biased CD4(+) T cell differentiation was independent of any crosstalk between CD4(+) T cells and dendritic cells and was mediated via direct exposure of CD4(+) T cells to palmitate, leading to increased activation of a PI3K p110delta-Akt-dependent pathway upon priming. PMID:28190771
18. miR-125b suppressed anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD expression. PMID:28122310
19. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kdelta or PKCbeta signaling pathways. PMID:26540567
20. We describe a family of two adults and three children with a gain of function mutation in PIK3CD, all with recurrent sinopulmonary infections and varied infectious and non-infectious complications. Sequencing of PIK3CD confirmed a known heterozygous mutation c3061G>A, p.E1021K in all affected family members. The two adults have primary sclerosing cholangitis without C. parvum infection. PMID:25352054
21. study concludes that activating mutations in PIK3CD may cause immunodeficiency in patients with a complex phenotype combining defective B and T cell responses, but are less likely to be discovered in patients where only the humoral arm of the immune response is affected and naive T cell numbers are normal PMID:26437962
22. work identifies FAK as a target of p110delta PI3K that links RhoA with PTEN and establishes for the first time that PTEN is a substrate of FAK-mediated Tyr phosphorylation PMID:26251180
23. Studies indicate that phosphatidylinositol-45-bisphosphate 3-kinase 110 kDa catalytic subunit (PIK3CD p110delta) have been described (N334K, C416R, E525K and E1021K with the majority of cases carrying E1021K) as a cause for primary immunodeficiency. PMID:26286043
24. Impaired signaling and protein synthesis through the PI3K catalytic subunit p110delta is an underlying molecular defect and potential treatment target in select autism spectrum disorders. PMID:26770665
25. Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs. PMID:26265781
26. Gestational diabetes mellitus is accompanied by leukocyte PIK3CD overexpression associated with reduced plasma LDL-C and TC levels, as well as with hyperglycaemia and elevated leukocyte SIRT1 mRNA. PMID:24549598
27. These results collectively indicate that inducible PI3Kdelta plays a crucial role in persistent activation of PI3K-Akt in fibroblast-like synoviocytes, and in the formation of a hypertrophic synovial lining. PMID:24716596
28. Data indicate a series of quinolinylpurines as potent and selective PI3Kdelta kinase inhibitors with in vivo efficacy as measured by two rodent disease models of inflammation and autoimmune disease. PMID:25469863
29. Expression of functional S1PR1 is reduced by B cell receptor signaling and increased by inhibition of PIK3CD but not SYK or BTK in chronic lymphocytic leukemia cells. PMID:25632006
30. The p110delta PI3K-selective compound CAL-101 (Idelalisib) did not inhibit markers of PI3K activity in cancer or stromal cells. PMID:24648465
31. Patients with activated phosphoinositide 3-kinase delta syndrome (mutation in PIK3CD) develop B-cell lymphomas. PMID:24698326
32. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. PMID:24610295
33. PIK3CD was inversely correlated with miR-663 in glioblastoma specimens and predicted poor prognosis of patients with glioblastoma PMID:24523440
34. PI3K p110delta uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of juvenile myelomonocytic leukemia. PMID:24553178
35. PIK3CD is a target gene of miR-125b in Ewing's sarcoma cells. RT-PCR and western blot assays identify over-expression of miR-125b that suppresses the expression of PIK3CD mRNA and protein. PMID:24517182
36. PI3Kdelta contributes to multiple aspects of the pathogenic FLS behavior in RA. These observations, together with previous findings that PI3Kdelta regulates FLS growth and survival PMID:24470496
37. Study reveals functional and mechanistic links between miRNA-30b and oncogene KRAS, PIK3CD and BCL2 in the pathogenesis of colorectal carcinoma. PMID:24293274
38. Data indicate that patients with combined immunodeficiency disease who share gain-of-function mutations in PIK3CD (p110delta), resulting in hyperactivation of mTOR signaling and skewed the differentiation of CD8+ T cells. PMID:24165795
39. this study found E1021K in 17 patients with activated PI3K-delta syndrome (APDS), from seven unrelated families with, but not among 3346 healthy subjects. PMID:24136356
40. The expression of PIK3CD is inversely correlated with miR-30a levels in metastatic colorectal carcinoma tissues. PMID:23486085
41. These results suggest that PI3Kdelta mediates dsRNA-induced upregulation of B7-H1 without affecting the activation of NF-kappaB. PMID:23660190
42. Studies indicate that the research with phosphoinositide 3-kinase p110-delta (p110delta) in chronic lymphocytic leukemia (CLL) have led to a more fundamental understanding of CLL signaling defects. PMID:22711705
43. PIK3CD shows evidence of association with schizophrenia, and is a previously undescribed therapeutic target for the treatment of psychiatric disorders. PMID:22689948
44. p37delta appears to be a new tumor-specific isoform of p110delta with growth-promoting properties PMID:22020336
45. PI3 kinase delta is a key regulator of synoviocyte function in rheumatoid arthritis. PMID:22433439
46. PI3K p110delta is important for TGFB1 induced production of the contractile proteins calponin and alpha-SMA and the proinflammatory cytokine IL-6 PMID:22015454
47. present a detailed biochemical and bioinformatic characterization of p110delta gene regulation, demonstrating that PIK3CD has distinct promoters, some of which can be dynamically activated by pro-inflammatory mediators PMID:22375552
48. Findings suggest that excessive PI3Kdelta activity is characteristic in Hodgkin lymphoma (HL) and support clinical evaluation of GS-1101, alone and in combination, as targeted therapy for HL. PMID:22210877
49. p110delta-dependent translocation of exogenous CSF-1 to the nucleus-associated CSF-1Rs, correlating with a prominent role of p110delta in activation of the Rab5 GTPase, a key regulator of endocytic trafficking PMID:22084313
50. Isoform specific targeting of PI3Kdelta may be beneficial in the treatment of glioblastoma multiforme by specifically inhibiting tumour cell migration capacity. PMID:22079609

Show More

Hide All

HGNC: 8977

UNIGENE: Hs.518451

KEGG: hsa:5293

STRING: 9606.ENSP00000366563

OMIM: 602839